ESTRO 2024 - Abstract Book

S2442

Clinical - Urology

ESTRO 2024

Conclusion:

Men with prostate cancer with lower skeletal muscle are at increased risk of late toxicities after radiotherapy. Results need to be validated in external cohorts but our results suggest that individualised prehabilitation or pharmaceutical interventions to protect muscle, prior to radiotherapy, could reduce treatment related toxicities and improve quality of life.

Keywords: prostate, body composition, radiotherapy toxicity

References:

[1] Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271-6.